Cancer

Salt AI announces new life sciences offering and ongoing partnership with Ellison Medical Institute

LOS ANGELES, March 12, 2025 /PRNewswire/ -- Salt AI, founded by the high-performance computing (HPC) team behind MySpace, today announces its…

10 months ago

Advarra Unveils Oncology Research Pulse

Content-Driven Program Brings Together Clinical Trial Stakeholders to Foster Knowledge Sharing and Collaboration in Cancer Research COLUMBIA, Md., March 12,…

10 months ago

Advarra Unveils Oncology Research Pulse

Content-Driven Program Brings Together Clinical Trial Stakeholders to Foster Knowledge Sharing and Collaboration in Cancer Research COLUMBIA, Md., March 12,…

10 months ago

Next-Gen Cancer Treatment: Rakovina’s AI-Driven ATR Inhibitors Enter Preclinical Testing

Harnessing generative AI to develop targeted therapies for DNA damage response, including hard-to-treat central nervous system malignanciesVANCOUVER, British Columbia, March…

10 months ago

Dogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward

Largest shareholder, CK Life Sciences Int’l., (Holdings) Inc. agrees to conversion of debt into equity, removing all existing debt from…

10 months ago

Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial

Encouraging Safety Profile Supports Progression Toward First Dual-Administration of Selective A2A and A2B Antagonists in PatientsDOVER, Del., March 12, 2025…

10 months ago

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a leading public health…

10 months ago

CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates

Late-breaking clinical and first translational data from BOND-003 Cohort C will be presentedIRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) --…

10 months ago

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)

Trial for this rare genetic disease to be conducted by NIH/NIAID in partnership with Corvus ITK inhibition intended to address…

10 months ago

Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities

Dr. Anatoly Dritschilo remains Chairman of the Board and Co-CEO overseeing scientific and clinical trial activitiesGAITHERSBURG, Md., March 12, 2025…

10 months ago